For colorectal cancer (CRC), lactoferrin-modified liposomes (LF-lipo) enhanced tumor-selective delivery of GA by targeting low-density lipoprotein receptor-related protein 1 (LRP-1), while simultaneously inducing immunogenic cell death (ICD) and reprogramming tumor-associated macrophage (TAM) polarization, thereby activating systemic anti-tumor immunity (Wang R. et al., 2023). Here, LRP1 is linked to colorectal cancer.